Literature DB >> 28082340

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.

Nicola Gökbuget1, Gerhard Zugmaier2, Matthias Klinger3, Peter Kufer3, Matthias Stelljes4, Andreas Viardot5, Heinz A Horst6, Svenja Neumann6, Monika Brüggemann6, Oliver G Ottmann7, Thomas Burmeister8, Dorothea Wessiepe9, Max S Topp10, Ralf Bargou11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28082340      PMCID： PMC5395124          DOI： 10.3324/haematol.2016.153957

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

Authors:  Matthias Klinger; Christian Brandl; Gerhard Zugmaier; Youssef Hijazi; Ralf C Bargou; Max S Topp; Nicola Gökbuget; Svenja Neumann; Mariele Goebeler; Andreas Viardot; Matthias Stelljes; Monika Brüggemann; Dieter Hoelzer; Evelyn Degenhard; Dirk Nagorsen; Patrick A Baeuerle; Andreas Wolf; Peter Kufer
Journal:  Blood       Date:  2012-05-16       Impact factor: 22.113

2.  Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.

Authors:  Nicola Gökbuget; Michael Kneba; Thorsten Raff; Heiko Trautmann; Claus-Rainer Bartram; Renate Arnold; Rainer Fietkau; Mathias Freund; Arnold Ganser; Wolf-Dieter Ludwig; Georg Maschmeyer; Harald Rieder; Stefan Schwartz; Hubert Serve; Eckhard Thiel; Monika Brüggemann; Dieter Hoelzer
Journal:  Blood       Date:  2012-03-22       Impact factor: 22.113

3.  Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.

Authors:  Max S Topp; Nicola Gökbuget; Gerhard Zugmaier; Evelyn Degenhard; Marie-Elisabeth Goebeler; Matthias Klinger; Svenja A Neumann; Heinz A Horst; Thorsten Raff; Andreas Viardot; Matthias Stelljes; Markus Schaich; Rudolf Köhne-Volland; Monika Brüggemann; Oliver G Ottmann; Thomas Burmeister; Patrick A Baeuerle; Dirk Nagorsen; Margit Schmidt; Hermann Einsele; Gert Riethmüller; Michael Kneba; Dieter Hoelzer; Peter Kufer; Ralf C Bargou
Journal:  Blood       Date:  2012-09-28       Impact factor: 22.113

4.  Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.

Authors:  Gerhard Zugmaier; Nicola Gökbuget; Matthias Klinger; Andreas Viardot; Matthias Stelljes; Svenja Neumann; Heinz-A Horst; Reinhard Marks; Christoph Faul; Helmut Diedrich; Albrecht Reichle; Monika Brüggemann; Chris Holland; Margit Schmidt; Hermann Einsele; Ralf C Bargou; Max S Topp
Journal:  Blood       Date:  2015-10-19       Impact factor: 22.113

5.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

6.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

Authors:  Max S Topp; Nicola Gökbuget; Gerhard Zugmaier; Petra Klappers; Matthias Stelljes; Svenja Neumann; Andreas Viardot; Reinhard Marks; Helmut Diedrich; Christoph Faul; Albrecht Reichle; Heinz-August Horst; Monika Brüggemann; Dorothea Wessiepe; Chris Holland; Shilpa Alekar; Noemi Mergen; Hermann Einsele; Dieter Hoelzer; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

7.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Authors:  Max S Topp; Nicola Gökbuget; Anthony S Stein; Gerhard Zugmaier; Susan O'Brien; Ralf C Bargou; Hervé Dombret; Adele K Fielding; Leonard Heffner; Richard A Larson; Svenja Neumann; Robin Foà; Mark Litzow; Josep-Maria Ribera; Alessandro Rambaldi; Gary Schiller; Monika Brüggemann; Heinz A Horst; Chris Holland; Catherine Jia; Tapan Maniar; Birgit Huber; Dirk Nagorsen; Stephen J Forman; Hagop M Kantarjian
Journal:  Lancet Oncol       Date:  2014-12-16       Impact factor: 41.316

Review 8.  Blinatumomab: a historical perspective.

Authors:  Dirk Nagorsen; Peter Kufer; Patrick A Baeuerle; Ralf Bargou
Journal:  Pharmacol Ther       Date:  2012-08-24       Impact factor: 12.310

9.  Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.

Authors:  G Zugmaier; M S Topp; S Alekar; A Viardot; H-A Horst; S Neumann; M Stelljes; R C Bargou; M Goebeler; D Wessiepe; E Degenhard; N Gökbuget; M Klinger
Journal:  Blood Cancer J       Date:  2014-09-05       Impact factor: 11.037
  9 in total
  25 in total

Review 1.  Antibody-based therapies in patients with acute lymphoblastic leukemia.

Authors:  Shira Dinner; Michaela Liedtke
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  CAR T cells better than BiTEs.

Authors:  John C Molina; Nirali N Shah
Journal:  Blood Adv       Date:  2021-01-26

3.  Blinatumomab bridges the gap between leukemia and immunity.

Authors:  Takahiro Yamazaki; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-07-31       Impact factor: 8.110

Review 4.  Progress in adult ALL: incorporation of new agents to frontline treatment.

Authors:  Jessica Leonard; Wendy Stock
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

5.  Navigating the nexus of MRD and novel agents in ALL.

Authors:  Anjali S Advani; Edward A Copelan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 6.  Mechanisms of and approaches to overcoming resistance to immunotherapy.

Authors:  Liora Schultz; Rebecca Gardner
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 7.  New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.

Authors:  Joanna Pierro; Laura E Hogan; Teena Bhatla; William L Carroll
Journal:  Expert Rev Anticancer Ther       Date:  2017-07-05       Impact factor: 4.512

Review 8.  T cell-engaging therapies - BiTEs and beyond.

Authors:  Maria-Elisabeth Goebeler; Ralf C Bargou
Journal:  Nat Rev Clin Oncol       Date:  2020-04-02       Impact factor: 66.675

9.  Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.

Authors:  Jae H Park; Isabelle Rivière; Mithat Gonen; Xiuyan Wang; Brigitte Sénéchal; Kevin J Curran; Craig Sauter; Yongzeng Wang; Bianca Santomasso; Elena Mead; Mikhail Roshal; Peter Maslak; Marco Davila; Renier J Brentjens; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

10.  Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group.

Authors:  Lia Gore; S Percy Ivy; Frank M Balis; Eric Rubin; Katherine Thornton; Martha Donoghue; Samantha Roberts; Suanna Bruinooge; Jennifer Ersek; Nancy Goodman; Caroline Schenkel; Gregory Reaman
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.